ZYBERNO
Stock Report
Updated Aug 31, 2026

Definium Therapeutics, Inc. (DFTX)

Healthcare • NASDAQ

$40.98

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
14.0/100
POOR BUSINESS
Definium Therapeutics, Inc. (DFTX) scores 14/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-85.2%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.04x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-56.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Definium Therapeutics, Inc. (DFTX) stock report — Zyberno Score 14/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:40.98
Market Cap:$4.54B

Valuation Multiples (2)

P/B Ratio:4.94x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.92B

Price Action & Momentum (1)

% of 52-Week High:82.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-64.6%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$8.20
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-140.0%
Latest Earnings Filed:2026-08-06
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:6.95x
Quick Ratio:6.95x
Cash Ratio:4.17x

Leverage Analysis (3)

Debt To Equity Ttm:0.04x
Debt-to-Equity Ratio:0.04x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-33.13x
Times Interest Earned:-33.13

Capital Structure (4)

Working Capital:934,897,000.00
Cash And Cash Equivalents:655,267,000.00
Long Term Debt:$36.47M
Net Debt:-$618.80M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$227.54M

Bottom Line Performance (3)

-$353.79M
Income Before Tax:-$16.49M
Ebitda Ttm:-227,544,000.00

Operating Expenses (5)

Operating Expenses:227,544,000.00
R And D Expense:154,648,000.00
Sga Expense:72,896,000.00
Income Tax Expense:$0.00
Interest Expense:5,020,000.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$1.11B
Current Assets:$1.09B
Ppe Net:0.00
Goodwill:19,918,000.00
Intangible Assets:$527.00K

Liability Structure (4)

Total Liabilities:194,220,000.00
Current Liabilities:157,204,000.00
Long Term Debt:$36.47M
Short Term Debt:$0.00

Equity & Capital (3)

Equity:$918.68M
Retained Earnings:-$818.76M
Common Stock:0.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:37,222,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:9,639,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$144.77M$0.00

Investment Activities (1)

Investing Cash Flow:$42.00M

Financing Activities (3)

Financing Cash Flow:$5.31M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:7,529,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-3.44
-$3.36
Earnings Per Share Ttm:-$3.20

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.19

Book Value & Capital (2)

Book Value Per Share:$8.30
Cash Per Share:5.92

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):33.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:DFTX
Company Name:Definium Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:110.68M
Shares Outstanding Basic:110.68M
Shares Outstanding Diluted:110.68M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 01:28:56 UTC
Data Timestamp:2026-08-31T01:28:56.955830
Scroll to Top